Komipharm International Australia

Komipharm International Australia is a biopharmaceutical company and a subsidiary of the South Korean-based Komipharm Co., Ltd. The company is primarily focused on the clinical development of its lead candidate, Kominox (sodium meta-arsenite), for the treatment of various cancers and the management of cancer-related pain. Kominox is an orally administered small molecule that targets telomeres to induce apoptosis in cancer cells. The Australian subsidiary oversees clinical trials and regulatory submissions within the Australian market, specifically targeting indications such as prostate cancer and terminal cancer pain. Their mission is to develop innovative oncological treatments that improve patient quality of life through non-opioid pain management and targeted anti-tumor activity.